INSM

Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes

Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028

INSM Stock: Over 15% Decrease Intraday Explanation

Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028

Insmed Incorporated (INSM) CEO Will Lewis on Q1 2021 Results - Earnings Call Transcript

Insmed Reports First Quarter 2021 Financial Results and Provides Business Update

ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with MDR